Global Biosimulation Market accounted for US$ 2113.91 billion in 2020 and is estimated to be US$ 8969.47 billion by 2030 and is anticipated to register a CAGR of 15.4%. Biosimulation is a relatively new concept in the drug development industry, and it is based on defining biological systems in mathematical expressions, capturing biological constituents and their interactions, and modelling the behavior of a system in various scenarios. Biosimulation employs a mathematical description of real-world processes within the human body, which is expressed as a series of interconnected differential equations. Differential equations are used to express the interactions between elements, allowing simulation approaches to anticipate the system's behavior and the amounts of biological elements over time.

**The report " Global Biosimulation Market, By Product and Services (Software (Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Prediction Software, and Toxicity Prediction Software), and Services (In-house Services and Contract Services)), By Application (Drug Discovery (Target Identification and Validation and Lead Identification and Optimization),and Drug Development (Preclinical Testing (PK/PD and ADME/TOX) and Clinical Trials)), By End User (Pharmaceutical and Biotechnology Organizations, Contract Research Organization, and Academic Research Institutions), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029’’**

**Key Highlights:**

* In June 2020, The PhoenixTM platform, the industry gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modelling and simulation software, has been updated to version 8.3 by the global leader in biosimulation.
* In December 2021, Simcyp Simulator Version 21, an update to the Company's population-based modelling and simulation platform, has been released by Simcyp, a global pioneer in biosimulation. To test new drug formulations, define first-in-human dosing, optimize clinical study design, and anticipate drug-drug interactions, the Simcyp Simulator is utilized throughout the drug development process.

**Analyst View:**

One of the important factors driving market expansion is the increasing number of drug relapse instances caused by drug resistance in diseases such as cancer, TB, and other bacterial infections. This is expected to increase the clinical urgency of incorporating biosimulation into the early stages of medication development. Increased healthcare expenditures, as well as technological breakthroughs in the field of biosimulation, are major drivers driving market expansion.

*Browse 60 market data tables\* and 35 figures\* through 140 slides and in-depth TOC on “****Global Biosimulation Market, By Product and Services (Software (Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Prediction Software, and Toxicity Prediction Software), and Services (In-house Services and Contract Services)), By Application (Drug Discovery (Target Identification and Validation and Lead Identification and Optimization),and Drug Development (Preclinical Testing (PK/PD and ADME/TOX) and Clinical Trials)), By End User (Pharmaceutical and Biotechnology Organizations, Contract Research Organization, and Academic Research Institutions), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029****”*

*To know the upcoming trends and insights prevalent in this market, click the link below****:***

<https://www.prophecymarketinsights.com/market_insight/global-biosimulation-market-247>

**Key Market Insights from the report:**

Global Biosimulation Market accounted for US$ 2113.91 billion in 2020 and is estimated to be US$ 8969.47 billion by 2030 and is anticipated to register a CAGR of 15.4%. Global Biosimulation market is segmented into product and service, application, end-user and region.

* Based on Product and Services, the Global Biosimulation Market is segmented into Software (Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Prediction Software, and Toxicity Prediction Software), and Services (In-house Services and Contract Services).
* Based on Application, the Global Biosimulation Market is segmented into Drug Discovery (Target Identification and Validation and Lead Identification and Optimization), and Drug Development (Preclinical Testing (PK/PD and ADME/TOX) and Clinical Trials)).
* Based on End-user, the Global Biosimulation Market is segmented into Pharmaceutical and Biotechnology Organizations, Contract Research Organization, and Academic Research Institutions.
* By Region, the Global Biosimulation Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to account for major revenue share as compared to that of other regions.

**Competitive Landscape & their strategies of Global Biosimulation Market:**

The key players in the global Biosimulation market includes Simulations Plus, Inc., Certara, LP., Genedata AG, Compugen Inc., Dassault Systemes (Accelrys), LeadScope, Inc., Schrödinger, LLC.